Ernst Lengyel to Cystadenocarcinoma, Serous
This is a "connection" page, showing publications Ernst Lengyel has written about Cystadenocarcinoma, Serous.
Connection Strength
4.279
-
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
Score: 0.879
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 Oct; 34(10):1630-1638.
Score: 0.851
-
Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Int J Gynecol Cancer. 2024 10 07; 34(10):1630-1638.
Score: 0.836
-
The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.
Score: 0.556
-
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
Score: 0.480
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
Score: 0.218
-
Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.
Score: 0.129
-
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.
Score: 0.113
-
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
Score: 0.110
-
The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.
Score: 0.080
-
Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94.
Score: 0.027